Onxeo SA
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; an… Read more
Onxeo SA (C4X) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.197x
Based on the latest financial reports, Onxeo SA (C4X) has a cash flow conversion efficiency ratio of -0.197x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.56 Million) by net assets (€23.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Onxeo SA - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Onxeo SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Onxeo SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Onxeo SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RELATECH S.P.A.
F:8EP
|
N/A |
|
Franklin Street Properties Corp
NYSE MKT:FSP
|
0.006x |
|
Socar Inc.
KO:403550
|
-0.170x |
|
Daemyoung Energy Co Ltd
KQ:389260
|
-0.003x |
|
Mi Chang Oil
KO:003650
|
0.024x |
|
Fynske Bank A/S
CO:FYNBK
|
0.001x |
|
Avantium Holding BV
AS:AVTX
|
-0.253x |
|
AGF A/S NAM.
F:5IN
|
N/A |
Annual Cash Flow Conversion Efficiency for Onxeo SA (2013–2024)
The table below shows the annual cash flow conversion efficiency of Onxeo SA from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-8.27 Million | €-12.46 Million | 1.508x | +228.33% |
| 2023-12-31 | €14.80 Million | €-17.39 Million | -1.175x | -177.05% |
| 2022-12-31 | €22.27 Million | €-9.44 Million | -0.424x | -62.95% |
| 2021-12-31 | €32.94 Million | €-8.57 Million | -0.260x | -61.51% |
| 2020-12-31 | €29.04 Million | €-4.68 Million | -0.161x | +64.01% |
| 2019-12-31 | €17.20 Million | €-7.70 Million | -0.448x | -80.44% |
| 2018-12-31 | €45.40 Million | €-11.27 Million | -0.248x | +56.24% |
| 2017-12-31 | €49.87 Million | €-28.28 Million | -0.567x | -202.99% |
| 2016-12-31 | €94.09 Million | €-17.61 Million | -0.187x | +16.77% |
| 2015-12-31 | €102.80 Million | €-23.12 Million | -0.225x | -255.14% |
| 2014-12-31 | €121.97 Million | €-7.72 Million | -0.063x | +96.46% |
| 2013-12-31 | €7.89 Million | €-14.09 Million | -1.786x | -- |